Novo Nordisk (NVO) and KKR's (KKR) joint acquisition of Sylvan International Biotechnology in China was cleared by the EU's antitrust review, the European Commission said Wednesday.
The Commission said it found that the proposed transaction would not raise competition concerns as the joint venture would have "negligible activities" in the European Economic Zone.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.